SCHEMBL196520

SCHEMBL196520

[O]C(=O)c1ccc2ccccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.71
CES1 P23141 1/20 0.71
HPGD P15428 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
EGFR P00533 1/20 0.59
TP53 P04637 1/20 0.59
CYP3A4 P08684 1/20 0.59
MAPT P10636 1/20 0.59
PKM P14618 1/20 0.59
ALOX15 P16050 1/20 0.59
ALOX12 P18054 1/20 0.59
JAK1 P23458 1/20 0.59
MAPK1 P28482 1/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
PTPN1 P18031 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL29219474 0.98 CES2 (0.68) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL3601971 0.93 CES2 (0.61) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL29613672 0.83 CES2 (0.74) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL30250451 0.83 CES2 (0.74) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL941698 0.83 CES2 (0.74) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL7220072 0.83 CES2 (1.00) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL31032483 0.83 CES2 (1.00) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL21817642 0.83 ALDH1A1 (0.70) CES2CES1HPGDKDM4EALDH1A1
Beta-Naphtoic Acid SCHEMBL29350891 0.82 CES2 (0.65) CES2CES1HPGDSMN1; SMN2KDM4E
Beta-Naphtoic Acid SCHEMBL98296 0.81 CES2 (0.71) CES2CES1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884882-B2 Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate FUJIFILM CORPORATION (JP) 2018-02-06 US claimed
EP-3109245-B1 METHOD FOR PRODUCTING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE FUJIFILM CORP (JP) 2018-01-03 EP claimed
EP-3109245-A1 METHOD FOR PRODUCTING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE FUJIFILM Corporation (JP) 2016-12-28 EP claimed
US-20160355536-A1 METHOD FOR PRODUCING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE FUJIFILM CORPORATION (JP) 2016-12-08 US claimed
US-5597776-A ANTAGONIST FOR HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1997-01-28 US claimed
EP-0537463-A2 Substituted pyrido(2,3-d)pyrimidines as antidotes BASF Aktiengesellschaft (DE) 1993-04-21 EP claimed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP claimed
US-3930866-A MAGENTA FUJI PHOTO FILM CO., LTD. (JA) 1976-01-06 US claimed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 WO disclosed
US-20240239922-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-07-18 US disclosed
EP-3632441-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DAY ONE BIOPHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
CN-118344346-A Heterocyclic compounds and their use 武田药品工业株式会社 2024-07-16 CN disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
EP-3782986-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-07-10 EP disclosed
US-3960571-A 1-PHENYL-2-PYRAZOL-5-ONE MAGENTA COLOR FORMING COUPLER Fuji Photo Film Co., Ltd. (JA) 1976-06-01 US disclosed
US-3943153-A BACTERICIDES MERCK & CO., INC. (US) 1976-03-09 US disclosed
US-3936462-A CNS DEPRESSANT, ANALGESIC STERLING DRUG INC. (US) 1976-02-03 US disclosed
US-3935016-A Silver halide color photographic materials containing 3-anilino-5-pyrazolone couplers FUJI PHOTO FILM COMPANY, LTD. (JA) 1976-01-27 US disclosed
US-3935015-A Silver halide color photographic materials containing 3-anilino-5-pyrazolane couplers FUJI PHOTO FILM CO., LTD. (JA) 1976-01-27 US disclosed
US-3930866-A MAGENTA FUJI PHOTO FILM CO., LTD. (JA) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 CES2 3781/4885CES1 2784/4885HPGD 3623/4885
US-20160355536-A1 METHOD FOR PRODUCING THIOLANE SKELETON-TYPE GLYCOCONJUGATE, AND THIOLANE SKELETON-TYPE GLYCOCONJUGATE ST6GAL1, FUT6, FUT5 CES2 699/4885CES1 921/4885HPGD 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.